Covid19 Clinical Trial
Official title:
COVID-19 IgG Antibodies in the Serum of Recovered Patients: a Longitudinal Study
Coronavirus disease 2019 (COVID‐19) is an infectious disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS‐CoV‐2), which first appeared in China, in December
2019 and is now spreading worldwide and poses a great threat to public health. In 12th July
2020, the total number of cases worldwide was about 13 million cases with case fatality rate
of 4.4% and in Egypt the total cases was 81158 and case fatality rate was 4.6%. (1,2).
In recent years, novel coronaviruses emerge periodically in different areas around the world.
Severe acute respiratory syndrome coronavirus (SARS‐CoV) occurred in 2002, which reportedly
infected 8422 people with about 10% case fatality rate (3). Middle East respiratory syndrome
coronavirus (MERS‐CoV) was first identified in 2012 in Saudi Arabia, bringing a total of 1401
MERS‐CoV infections, and about 35% case fatality rate (1). All the infection cases and recent
epidemics show that coronaviruses impose a continuous threat to human beings and the economy
as they emerge unexpectedly, spread easily, and lead to catastrophic consequences.
As the number of recovered patients with COVID-19 continues to be increasing, the strength
and duration of immunity after infection is an important point to be studied. Moreover,
understanding this issue is a critical point for controlling this epidemic as they are the
key for herd immunity and for informing decisions on how and when to ease physical distancing
restrictions and to be ready for other waves of the infection. There is currently no evidence
if the people who have recovered from COVID-19 have antibodies and protected from a second
attack of infection or future wave of this pandemic or not. Therefore, we will carry out a
longitudinal study of immunity in recovered patients to assess SARS-Cov2 patients' risk for
future reinfection.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
| Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
| Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
| Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
| Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
| Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
| Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
| Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
| Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
| Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
| Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
| Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
| Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
| Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
| Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
| Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
| Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
| Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
| Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |